Over the last 12 months, MoonLake Immunotherapeutics insiders reported no purchases and 9 sales totaling $9.3M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 1,100 | $20 | $22K | — | plan · indirect |
| Jul 22, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 52,448 | $20.02 | $1.0M | -1.9% | plan · 2 tranches · indirect |
| Jul 20, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 43,700 | $20.09 | $878K | -1.6% | plan · indirect |
| Jul 15, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 16,105 | $20.01 | $322K | -0.6% | plan · indirect |
| Jul 10, 2026 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 102,225 | $20.02 | $2.0M | -3.6% | plan · 2 tranches |
| Jul 1, 2026 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 47,775 | $20.03 | $957K | -1.6% | plan |
| Jun 22, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 39,120 | $22.04 | $862K | -3.4% | plan |
| Jun 18, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 17,876 | $19.67 | $352K | -1.5% | plan · 2 tranches |
| Jun 17, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 150,000 | $19.01 | $2.9M | -5% | plan · 3 tranches · indirect |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MLTX feed.